4
Aug 2026
3D DNA organization in rare immune cells can explain Crohn's disease risk
A new study co-led by Prof. Valeriya Malysheva, group leader at the VIB-UAntwerp Center for Molecular Neurology, has been published in Nature Genetics.

Innovators and start-ups in healthcare and biotech are experts in their innovation’s scientific and technical domain but often struggle with navigating the complex world of the healthcare industry.
If you want to objectively show the advantages and competitiveness of your innovation to potential investors, future users, (reimbursement) payers or even the media, you can greatly benefit from Mercury Pharmaceuticals’s Health Innovation Assessment solution.
By making use of robust methods to collect and analyse data, Health Innovation Assessment (HIA) aims to comprehensively assess the added value of (bio-)medical and healthcare innovations. HIA takes into account true multi-stakeholder perspectives on value assessment and the realm of marketplace decision making.
Clinical trials are very important as it allow us to evaluate the effectiveness of new drugs, new devices, preventative strategies or treatment strategies. It also enables us to discover better ways for patients' care.
- Learn more
Our mission remains constant as we endeavor to deliver novel medicines to patients with cancer, treating solid tumors with high unmet medical needs in well-defined patient populations that are currently not well supported.
- Learn more
Whether you're looking to manufacture toxicology batches or cGMP material for clinical trials, we can help you expedite molecules to clinic with full transparency.
- Learn more
4
Aug 2026
A new study co-led by Prof. Valeriya Malysheva, group leader at the VIB-UAntwerp Center for Molecular Neurology, has been published in Nature Genetics.
4
Aug 2026
Working from home is often seen as a good solution for new mothers, but a new Washington State University study reveals that the blurred boundaries between home and work can introduce barriers to sustained breastfeeding.
4
Aug 2026
Insilico Medicine ("Insilico"), a clinical-stage generative artificial intelligence (AI)-driven biotechnology company, today announced the publication of a collaborative study in the journal npj Precision Oncology.
4
Aug 2026
Radiopharmaceutical therapy (RPT) has made great strides over the last 50 years, having only recently received FDA approval to treat prostate cancer. But despite the progress-and billions of dollars of industry investments-one area that has lagged behind is dosing, which is still one-size-fits-all.